Comparative Pharmacology
Head-to-head clinical analysis: BRIELLYN versus PORTIA 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRIELLYN versus PORTIA 28.
BRIELLYN vs PORTIA-28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol (estrogen) and norethindrone (progestin) that inhibits gonadotropin secretion, primarily suppressing ovulation and altering cervical mucus and endometrial lining.
Combination oral contraceptive: estrogen (ethinyl estradiol) suppresses gonadotropin release, inhibiting ovulation; progestin (levonorgestrel) alters cervical mucus and endometrial lining.
BRIELLYN (ethinyl estradiol / norethindrone) 1 tablet (0.035 mg ethinyl estradiol / 0.5 mg norethindrone) orally once daily at the same time each day.
One tablet (levonorgestrel 0.15 mg, ethinyl estradiol 0.03 mg) orally once daily
None Documented
None Documented
12-19 hours; clinical context: steady state reached in 3-5 days, dosing adjustment recommended in renal impairment
Levonorgestrel: 24-30 hours; ethinyl estradiol: 12-15 hours. Clinical context: Steady-state achieved within 5-7 days.
Approximately 60% renal excretion of metabolites, 40% fecal/biliary elimination
Renal (60-70% as metabolites, 20-30% as levonorgestrel/ethinyl estradiol glucuronides), fecal (10-20%), biliary (minor).
Category C
Category C
Oral Contraceptive
Oral Contraceptive